ReviewDiscover oncology2024

Combination of BCL-2 inhibitors and immunotherapy: a promising therapeutic strategy for hematological malignancies.

Xiaohuan Peng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.